3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Hypoxia
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Melanoma
1
Gastrointestinal Stromal Tumors
1
Interventions
Imatinib Mesylate
6
Laparoscopy
3
Surgical Procedures, Operative
2
spartalizumab
1
ripretinib
1
regorafenib
1
ponatinib
1
famitinib
1
apixaban
1
anlotinib
1
Thoracic Surgery, Video-Assisted
1
TH 302
1
Surveys and Questionnaires
1
Surgical Tape
1
Sunitinib
1
Rivaroxaban
1
Oxaliplatin
1
Nivolumab
1
Liver Transplantation
1
Ipilimumab
1
Interviews as Topic
1
Endoscopic Mucosal Resection
1
Dasatinib
1
Dalteparin
1
Blood Specimen Collection
1
Biopsy
1
68Ga-NOTA-RM26
1
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Gastrointestinal Stromal Tumors
×
TH 302
×
Clear all
NCT01381822
2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1
Unknown
58 enrolled